Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the dregs of retail pharmacies…
All the institutions bought above $6, so many blew out of their positions
The truth: $3.39m marketcap. No chance for recovery. GE dropped their usage.
It is done, finished, kaput. Delisted shortly
$NDRA pic.twitter.com/TMtjLCnkID
The institutions were forced to sell. I can’t imagine an institution wanting to show this as one of their holdings in the second quarter reveal.
Françoise ride is just about over. He’s pumped this for five years and none of his promises of come true. It’s over.
😭 The truth: $3.39m marketcap.
It is done, finished, kaput. Delisted shortly
$NDRA pic.twitter.com/TMtjLCnkID
Don’t waste your or their time. Institutions have had enough.
Agreed. The BOD must be working toward a replacement..
They deserve it! Their stock options are underwater..
Advance Market Analytics published a new research publication on "Dystonia Drugs Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Dystonia Drugs market was mainly driven by the increasing R&D spending across the world. Some of the key players profiled in the study are Pfizer (United States), Novartis (Switzerland), Sanofi (France), Merck(United States), Aspen Pharma (South Africa), Merz Pharma GmbH & Co. KGaA (Germany), Ipsen (France), Revance Therapeutics, Inc. (United States), Boston Scientific Corporation(United States), Allergan, Inc.(Ireland), Shineway (China).
Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/118658-global-dystonia-drugs-market?utm_source=OpenPR&utm_medium=Lal
Scope of the Report of Dystonia Drugs
The research done by the American Association of Neurological Surgeons, ****dystonia affects up to 250,000 people in the United States.**** Dis a type of neurological movement disorder that is characterized by irregular uncontrollable muscle contractions followed by involuntary twisting body parts and abnormal posture. Dystonia affects women more than men. The symptoms of dystonia are cramps in the foot, difficulty in speech, uncontrollable blinking, etc. Dystonia drugs can help the condition the common categories of drugs used in dystonia condition are, anticholinergic, benzodiazepine, dopamine drugs, and others. Dystonia is certifiably not a single disease yet a disorder - a bunch of indications that can't be attributed to a solitary reason yet share normal components. A few types of Dystonia may influence a particular body area, for example, the neck, face, jaw, eyes, appendages, or vocal cords.
Holy heck, this stuff works! Word-of-mouth should be the only thing Revance needs now, and the training of more injectors. Thanks Go Seek!
Crushed
Thanks Go Seek. Your Instagram links keeps the hope alive.
Yes, this will all of a sudden engage and off she goes. Barrick has little net debt now..
A toxic toxin company..(tm)
Doesn’t have the efficacy..
Thank you wowster. I don’t have the ability now to flush that out..
Curious, how large is the Perceptive's purchase?
Whew, not even a positive tic up in the price today.
Soma, thank you as that is a very important point…
The shorts knew in February:
FWIW (a sliver of ‘good news’ could make things finally swing 🆙)
RVNC / Short Interest
( new #’s on 5/15)
04/30/2024~12,288,926
04/15/2024~11,625,272
03/28/2024~13,551,210
03/15/2024~10,865,757
02/29/2024~11,879,422
On average about 7days to cover …
This should not be via a prescription anymore.
Dew, is this the worst stock pick in your investing life??
😭 The truth: $3.39m marketcap.
It is done, finished, kaput. Delisted shortly
$NDRA pic.twitter.com/TMtjLCnkID
— Billy Ocean (@BillyOcean4532) May 10, 2024
The patents aren’t worth squat
Operating expense is $100M, revenue is $60M approximately.. short $40M per quarter. How can they expect to be even when generating $280M revenue 2024 and be break even in 2025? Unless operating expense can cut down to $70M? Just curious by 2025 meaning end of 2025 to break even?
You are intermixing years. $280M is revenue for 2024, not 2025. No estimate for 2025 revenue was given. Foley said the CD sales will really ramp in 2025.
so if Revance can just meet or exceed their guidance for revenue and expenses for 2024 I expect the stock to be considerably higher by the end of the year.- Agreed
Launch of CD tomorrow I think.
This has turned into another Ariad…..
Only a $3.6 million market cap. There is no way out for this one.. even selling all of Françoise Rolexes isn’t gonna help.
Bad decision. There is a lot going on, and they didn’t what to share?
It might be that the millennials steer this more than the baby boomers now
As you whine and pout, RVNC gains traction. The KOL coverage here was great..
Soma, thank you for taking the time post your informative information.
The number of posters here buying this as it was falling day after day over the last year is startling.
This is at the point where the CEO announces he is leaving the company
This feels different.
Down another 9% today, at $3.25. This is now a question of survival in my opinion.
Sometimes being David is just not good enough against Goliath…..
Unfortunately, it is not accurate enough..